Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

Printer friendly version
Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
PRINCETON, N.J., Jan. 31 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
announced today that it is scheduled to present at the Merrill Lynch Global
Pharmaceutical, Biotechnology & Medical Device Conference at 9:20 a.m. ET on
Thursday, February 7, 2008. The event will be webcast live and will be available in
the Investor Relations section of the Medarex Web site at www.medarex.com. An
archived edition of the presentation will be available following the event.

    About Medarex

    Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. More than 30 of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase III clinical trials or the subject of
regulatory applications for marketing authorization. Medarex is committed to
building value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit its Web
site at www.medarex.com.

    Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.

SOURCE  Medarex, Inc.
    -0-                             01/31/2008
    /CONTACT:  Laura S. Choi, Investor Relations, +1-609-430-2880, ext. 2216, or
Jean Mantuano, Corporate Communications, +1-609-430-2880, ext. 2221, both of
Medarex, Inc./
    /Company News On-Call:  http://www.prnewswire.com/comp/108265.html /
    /Web site:  http://www.medarex.com /
    (MEDX)

CO:  Medarex, Inc. ST:  New Jersey IN:  MTC HEA IDC SU:  CCA

RB-JA -- NETH068 -- 6689 01/31/2008 16:00 EST http://www.prnewswire.com